X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sorafenib (94) 94
index medicus (79) 79
humans (71) 71
niacinamide - analogs & derivatives (57) 57
pharmacology & pharmacy (45) 45
oncology (32) 32
male (29) 29
animals (28) 28
female (27) 27
cancer (26) 26
antineoplastic agents (23) 23
antineoplastic agents - therapeutic use (23) 23
antimitotic agents (22) 22
pharmacokinetics (22) 22
phenylurea compounds (22) 22
antineoplastic agents - pharmacokinetics (20) 20
metabolites (19) 19
middle aged (19) 19
protein kinase inhibitors - therapeutic use (19) 19
analysis (18) 18
pharmacology/toxicology (18) 18
phenylurea compounds - administration & dosage (17) 17
phenylurea compounds - pharmacokinetics (17) 17
renal-cell carcinoma (17) 17
sunitinib (17) 17
carcinoma, hepatocellular - drug therapy (16) 16
hepatocellular carcinoma (16) 16
niacinamide - administration & dosage (16) 16
adult (15) 15
aged (15) 15
antineoplastic agents - adverse effects (15) 15
article (15) 15
liver neoplasms - drug therapy (15) 15
medicine & public health (15) 15
pyridines - pharmacokinetics (15) 15
pyridines - therapeutic use (15) 15
antitumor-activity (14) 14
multikinase inhibitor (14) 14
niacinamide - pharmacokinetics (14) 14
phenylurea compounds - therapeutic use (14) 14
protein kinase inhibitors - pharmacokinetics (14) 14
antineoplastic agents - administration & dosage (13) 13
protein kinase inhibitors - adverse effects (13) 13
refractory solid tumors (13) 13
antineoplastic agents - pharmacology (12) 12
benzenesulfonates - therapeutic use (12) 12
mice (12) 12
niacinamide - therapeutic use (12) 12
phase-i (12) 12
protein kinase inhibitors - administration & dosage (12) 12
protein kinase inhibitors - pharmacology (12) 12
pyridines - adverse effects (12) 12
dose-response relationship, drug (11) 11
hepatocellular-carcinoma (11) 11
raf kinase (11) 11
advanced hepatocellular-carcinoma (10) 10
antineoplastic agents - blood (10) 10
cancer research (10) 10
chemistry, analytical (10) 10
endothelial growth-factor (10) 10
liver cancer (10) 10
mass spectrometry (10) 10
neoplasms (10) 10
safety (10) 10
tyrosine kinase inhibitor (10) 10
benzenesulfonates - adverse effects (9) 9
benzenesulfonates - pharmacokinetics (9) 9
carcinoma, renal cell - drug therapy (9) 9
kidney neoplasms - drug therapy (9) 9
metabolism (9) 9
phenylurea compounds - adverse effects (9) 9
phenylurea compounds - blood (9) 9
pyridines - administration & dosage (9) 9
pyridines - blood (9) 9
tumors (9) 9
tyrosine kinase inhibitors (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
care and treatment (8) 8
chemotherapy (8) 8
disease-free survival (8) 8
drug interactions (8) 8
drug therapy (8) 8
factor receptor inhibitor (8) 8
in-vitro (8) 8
management (8) 8
neoplasms - drug therapy (8) 8
phenylurea compounds - pharmacology (8) 8
regorafenib (8) 8
reproducibility of results (8) 8
treatment outcome (8) 8
tyrosine (8) 8
aged, 80 and over (7) 7
angiogenesis (7) 7
apoptosis (7) 7
bay-43-9006 (7) 7
biochemical research methods (7) 7
biochemistry & molecular biology (7) 7
cell proliferation - drug effects (7) 7
double-blind (7) 7
hematology (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Best Practice & Research Clinical Gastroenterology, ISSN 1521-6918, 2006, Volume 20, Issue 2, pp. 315 - 326
There is still a substantial need for the development of new treatments for patients with pancreatic cancer. In this chapter, we will document that there is... 
sorafenib | epidermal growth factor receptor (EGFR) | thioredoxin | vascular endothelial growth factor (VEGF) | cetuximab | TNFerade | prostate specific cancer antigen (PSCA) | gastrin | thioredoxin reductase | vaccine | polo-like kinase | bevacizumab | hypoxia inducible factor alpha (HIF-1α) | gemcitabine | Gemcitabine | Epidermal growth factor receptor (EGFR) | Vascular endothelial growth factor (VEGF) | Vaccine | Thioredoxin | Thioredoxin reductase | Prostate specific cancer antigen (PSCA) | Bevacizumab | Sorafenib | Gastrin | Hypoxia inducible factor alpha (HIF-1α) | Polo-like kinase | Cetuximab | NUDE-MICE | hypoxia inducible factor alpha (HIF-I alpha) | MONOCLONAL-ANTIBODY | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | HYPOXIA-INDUCIBLE FACTOR-1-ALPHA | GEMCITABINE G | DOUBLE-BLIND | BEVACIZUMAB B | GASTROENTEROLOGY & HEPATOLOGY | DOSE-RATE | Niacinamide - analogs & derivatives | Gastrins - therapeutic use | Humans | Tegafur - therapeutic use | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Antibodies, Monoclonal, Humanized | Tumor Necrosis Factor-alpha - therapeutic use | Cancer Vaccines - therapeutic use | Cyclic N-Oxides - therapeutic use | Deoxycytidine - therapeutic use | Oxonic Acid - therapeutic use | Sulfonamides - therapeutic use | Adenoviridae - genetics | Deoxycytidine - analogs & derivatives | Drug Combinations | Pancreatic Neoplasms - therapy | Pyridines - therapeutic use | Monoclonal antibodies | Care and treatment | Drug therapy | Pancreatic cancer | Cancer
Journal Article
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 03/2006, Volume 7, Issue 4, pp. 453 - 461
Sorafenib is a small molecule inhibitor of several kinases involved in tumour proliferation and tumour angiogenesis including Raf, VEGFR and platelet derived... 
Raf kinase | renal cell carcinoma | sorafenib | VEGF | Renal cell carcinoma | Sorafenib | VON-HIPPEL-LINDAU | SUPPRESSOR GENE | DAYS ON/7 DAYS | ANTITUMOR-ACTIVITY | RENAL-CELL CARCINOMA | FACTOR RECEPTOR INHIBITOR | PHARMACOLOGY & PHARMACY | REFRACTORY SOLID TUMORS | PHASE-I | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | raf Kinases - antagonists & inhibitors | Humans | Pyridines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | raf Kinases - metabolism | Benzenesulfonates - pharmacokinetics | Carcinoma, Hepatocellular - drug therapy | Receptors, Vascular Endothelial Growth Factor - metabolism | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Carcinoma, Renal Cell - enzymology | Neovascularization, Pathologic - prevention & control | Antineoplastic Agents - pharmacokinetics | Carcinoma, Renal Cell - drug therapy | Carcinoma, Renal Cell - blood supply | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Liver Neoplasms - drug therapy | Treatment Outcome | Randomized Controlled Trials as Topic | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Kidney Neoplasms - enzymology | Melanoma - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Kidney Neoplasms - drug therapy | Kidney Neoplasms - blood supply
Journal Article
Der Onkologe, ISSN 0947-8965, 10/2006, Volume 12, Issue 10, pp. 1043 - 1053
Sorafenib ist ein oral wirksamer Multikinaseinhibitor mit mehreren Angriffspunkten an verschiedenen Serin-/Threonin- und Rezeptortyrosinkinasen. Sorafenib... 
VEGFR-2 and VEGFR-3 blocking | RAF-1 kinase and B-RAF kinase blocking | Sorafenib | VEGFR-2- und VEGFR-3-Hemmung | Randomisierte Phase-III-Studie | Renal cell cancer | RAF-1- und B-RAF-Kinase-Hemmung | Nierenzellkarzinom | Randomised phase III trials
Journal Article
Journal of Chromatography B, ISSN 1570-0232, 2009, Volume 877, Issue 3, pp. 269 - 276
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2011, Volume 67, Issue 4, pp. 751 - 764
To characterize the cardiovascular profile of sorafenib, a multitargeted kinase inhibitor, in patients with advanced cancer.Fifty-three patients with advanced... 
Hypertension | Cardiovascular adverse event (CAE) | Left ventricular ejection fraction (LVEF) | Medicine & Public Health | QT/QTc interval | Sorafenib | Oncology | Cancer Research | Cardiovascular profile | Pharmacology/Toxicology | CARDIAC TOXICITY | BEVACIZUMAB | HEART-FAILURE | SUNITINIB MALATE | CARDIOTOXICITY | ANTITUMOR-ACTIVITY | RENAL-CELL CARCINOMA | TYROSINE KINASE INHIBITORS | ONCOLOGY | PHARMACOLOGY & PHARMACY | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Area Under Curve | Humans | Middle Aged | Ventricular Function, Left - drug effects | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Benzenesulfonates - adverse effects | Neoplasms - drug therapy | Heart Rate - drug effects | Benzenesulfonates - pharmacokinetics | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Female | Aged | Antineoplastic Agents - pharmacokinetics | Blood Pressure - drug effects | Neoplasms - pathology | Electrocardiography, Ambulatory | Pyridines - therapeutic use | Medical colleges | Care and treatment | Safety and security measures | Oncology, Experimental | Research | Antineoplastic agents | Antimitotic agents | Complications and side effects | Cancer patients | Heart beat | Metabolites | Electrocardiogram | Electrocardiography | Cancer | QTc interval | Original
Journal Article
Journal Article
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 10/2010, Volume 15, Issue 5, pp. 512 - 514
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2011, Volume 68, Issue 1, pp. 239 - 245
Sorafenib is recommended for therapy of advanced hepatocellular carcinoma and renal cell carcinoma. Preclinical data indicate a relation between dose and... 
Validation | Medicine & Public Health | Sorafenib | Serum concentrations | Oncology | Cancer Research | Hepatocellular carcinoma | Pharmacology/Toxicology | HPLC | Peritoneal fluid | ADVANCED HEPATOCELLULAR-CARCINOMA | BAY-43-9006 | ASSAY | HUMAN PLASMA | SAFETY | RAF KINASE | RENAL-CELL CARCINOMA | RAF/MEK/ERK PATHWAY | ONCOLOGY | PHARMACOLOGY & PHARMACY | Peritoneal Xuid | REFRACTORY SOLID TUMORS | PHASE-I | Niacinamide - analogs & derivatives | Humans | Pyridines - pharmacokinetics | Kidney Neoplasms - metabolism | Phenylurea Compounds | Chromatography, High Pressure Liquid | Protein Kinase Inhibitors - adverse effects | Benzenesulfonates - adverse effects | Benzenesulfonates - pharmacokinetics | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Sensitivity and Specificity | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Carcinoma, Renal Cell - drug therapy | Protein Kinase Inhibitors - pharmacokinetics | Ascitic Fluid - chemistry | Liver Neoplasms - drug therapy | Protein Kinase Inhibitors - blood | Pyridines - blood | Liver Neoplasms - metabolism | Antineoplastic Agents - blood | Drug Monitoring | Kidney Neoplasms - drug therapy | Antimitotic agents | Liver cancer | Liquid chromatography | Antineoplastic agents | Analysis | Methods | Index Medicus
Journal Article